Quotables
"There is no reason anyone would want a computer in their home."
Ken Olsen, chairman and founder of Digital Equipment Corporation ; 1977
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8163958 | Levodopa prodrugs, and compositions and uses thereof Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. ... | 04/24/2012 |
| 8026396 | Processes for the preparation of optically active intermediates This invention relates to processes for the production of optically active 2-(disubstituted aryl)cyclopropylamine compounds and optically active 2-(disubstituted aryl)cyclopropane carboxamide compounds which are useful intermediates for the preparation of pharmaceut... | 09/27/2011 |
| 7847122 | Polymorphs of suberoylanilide hydroxamic acid The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inh... | 12/07/2010 |
| 7528282 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-in... | 05/05/2009 |
| 7442829 | Fluorine-containing monomer, fluorine-containing polymer and surface treating agent Disclosed is a fluorine-containing polymer having: (A) a repeating unit derived from a fluorine-containing monomer which is represented by the following formula: CH2═C(—X)—C(═O)—Y—[—(CH2)m-Z-] | 10/28/2008 |
| 7439394 | Cyclohexyl-1,4-diamine compounds Novel cyclohexyl-1,4-diamine compounds corresponding to formula I, processes for the production thereof, pharmaceutical compositions containing these compounds, methods of producing pharmaceutical compositions including the... | 10/21/2008 |
| 7432396 | Process for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-hydroxymethylcyclopropane The present invention provides a process for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-hydroxymethylcyclopropane, which comprises reacting 2-oxo-1-phenyl-3-oxabicyclo[3.1.0]hexane with diethylamine in the presence of alkali metal alkoxide. ... | 10/07/2008 |
| 7432289 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ... | 10/07/2008 |
| 7423067 | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are use... | 09/09/2008 |
| 7405307 | Biphenylcarboxamides useful as lipid lowering agents Biphenylcarboxamide compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia... | 07/29/2008 |
| 7390924 | Terphenyl derivatives, preparation thereof, compositions containing same The invention relates to terphenyl derivatives of formula: and to their preparation and to the pharmaceutical compositions comprising them. These compounds exhibit an antagonist activity with respect to CB1 | 06/24/2008 |
| 7348456 | Substituted amides Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are... | 03/25/2008 |
| 7342131 | Levodopa prodrugs, and compositions and uses thereof Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. ... | 03/11/2008 |
| 7326732 | EP2 receptor agonists A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 | 02/05/2008 |
| 7326731 | Muscarinic agonists The present invention relates to compounds of Formula I: Formula I which are agonists of the M-1 muscarinic receptor. ... | 02/05/2008 |
| 7326813 | Process for producing benzylamine derivative Disclosed is a process for producing a benzylamine derivative represented by the general formula (3): wherein X1, R1 and R2 are as defined below, which comprises reacting a benzyl... | 02/05/2008 |
| 7312368 | Method for selective reduction of aromatic compounds A method for the selective reduction of an aromatic compound. The present invention provides a method for pre-venting the reduction of at least one halogen substituted aromatic ring of an aromatic compound, while allowing the reduction of at least one functional gro... | 12/25/2007 |
| 7304065 | Melanin concentrating hormone antagonists The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provides a means for reducing body mass. The compounds of the present invention are selective against melanin concentrating hormone and do not hav... | 12/04/2007 |
| 7294643 | UK-1 analogues: methods of preparation and use The present invention includes a number of structural analogues of UK-1. A comparision of the anticancer activity of the UK-1 analogues with their ability to inhibit the growth of methicillin-sensitive and methicillin-resistant Staphylococcus aureus demonstra... | 11/13/2007 |
| 7285680 | β-alanine derivatives and the use thereof A compound of the general formula (I) (wherein the symbols are as defined in the description), or a prodrug or a salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is use... | 10/23/2007 |
| 7271280 | Process for preparing a biaryl compound A process for preparing an optically active biaryl compound the formula (4): which comprises reacting an aromatic sulfonic acid ester compound of the formula (1): ... | 09/18/2007 |
| 7268132 | Substituted thioacetamides The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases. ... | 09/11/2007 |
| 7259187 | Tropolone derivatives Tropolone derivatives represented by the formula (I), which have retinoid actions and are useful as active ingredients of medicaments [R1 to R4 represent hydrogen atom, an alkyl group, or an alkoxyl group; the ring represented by Ar represents ... | 08/21/2007 |
| 7259278 | Anti-S-phase tubulin ligands It is presently accepted that the mechanism of action for all anti-tumor tubulin ligands involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis (1). In this invention, we report a novel tubulin li... | 08/21/2007 |
| 7253194 | Compounds and inhibitors of phospholipases The present invention relates generally to amino acid derivatives and to methods of making the same. In particular, the invention relates to compounds bearing a stereochemical identity, that is, the same stereochemistry, with the chiral α-carbon of D-α-amino acids... | 08/07/2007 |
| 7241811 | Amide compounds for the potentiation of cholinergic activity Amide compounds of the formula: wherein R1 and R2 are taken together to form lower alkenylene, etc., R3 is aryl, etc., X is N, ... | 07/10/2007 |
| 7230000 | Methods and compositions utilizing quinazolinones Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity ... | 06/12/2007 |
| 7223888 | Mu opioid receptor ligands: methods of use and synthesis Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mamma... | 05/29/2007 |
| 7220781 | Meta-benzamidine derivatives as serine protease inhibitors Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted... | 05/22/2007 |
| 7208528 | Polyamine analogues as therapeutic and diagnostic agents Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine t... | 04/24/2007 |
| 7208630 | Heat shock protein 90 inhibitors Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol. ... | 04/24/2007 |
| 7205438 | Solvent recovery blends from diene production A diene production stream comprising a solvent recovery blend from diene production comprising one or more fouling agent, one or more extractive distillation solvent, and from about 1 ppm to about 1000 ppm of N,N-disubstituted amide. ... | 04/17/2007 |
| 7202233 | Alprazolam inclusion complexes and pharmaceutical compositions thereof A pharmaceutical composition an inclusion complex and methods for treating patients and preparing said complex disclosed for transmucosal delivery comprising an inclusion complex of (a) alprazolam and (b) a water soluble 2-hydroxypropyl-beta-cyclodextrin, and a phar... | 04/10/2007 |
| 7186861 | Z-substituted acrylamides, methods for production thereof and agents comprising the same Z-substituted acrylamides of formula (I), where the substituents have the following meanings: X═H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, with X in the 3- or 4-position, n=1 or 2, where X can be different if n=2, R1=alkyl, haloalkyl, cycloalkyl,... | 03/06/2007 |
| 7183318 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them The invention concerns compounds of formula (1): R-A-R′ wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R... | 02/27/2007 |
| 7183319 | Phenylethylamine derivatives and their use in the treatment of melanoma Novel mono- and dihydroxy phenylethylamine derivatives useful in treating melanoma are provided having the formulae (Ia, Ib or Ic). In the above formulae, Ra is hydrogen or —COORb, Rb is hydrogen or C1-6 alkyl; Re | 02/27/2007 |
| 7179946 | Copper complexes and their use The invention relates to copper complexes of phosphorus compounds, to a process for their preparation and to their use in catalytic coupling reactions. ... | 02/20/2007 |
| 7169813 | 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer A drug based on a metabolite of fenretinide, or N-(4hydroxyphenyl) retinamide (4-HPR), specifically 4-oxo-N-(4-hydroxyphenyl) retinamide (4-oxo-4-HPR), is used in the treatment of different kinds of tumors, in particular in the treatment of ovarian carcinoma, breast... | 01/30/2007 |
| 7160923 | Polyamine analogues as therapeutic and diagnostic agents Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine t... | 01/09/2007 |
| 7160922 | Hemihydrate of a selective functional M1 muscarine receptor agonist The present invention provides crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate, compositions thereof, methods of using the same, processes for making the same, and processes for ... | 01/09/2007 |
